As BioNTech Shifts Focus, Financial Winds Bring Tumultuous Changes and Strategic Ambitions
BioNTech is navigating financial challenges amidst its transition from COVID-19 vaccines to cancer treatments. Earnings dropped significantly, but the company still exceeded market expectations with revenue reaching €1.19 billion. Net…